Luzzatto G, Fabris F, Dal Bo Zanon R, Girolami A
Arzneimittelforschung. 1986 Jun;36(6):972-3.
Antiplatelet properties of AD 6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy-carboxyl- methoxycoumarin) have been studied in vitro and in vivo. The drug showed a marked inhibitory effect on platelet aggregation, beta-thromboglobulin (beta TG) release and thromboxane B2 (TxB2) production in vitro. However, such effects were seen only in the presence of high concentrations of the drug (10(-3) and 10(-4) mol/l) and completely disappeared at lower concentrations. No effect was seen in vivo following oral administration of 300 mg of the drug in a small group of volunteers. It can be concluded that in vitro properties of the drug cannot be surmised without due caution to indicate its potential clinical use.
已在体外和体内研究了AD 6（8-氯-3-β-二乙氨基乙基-4-甲基-7-乙氧基-羧基-甲氧基香豆素）的抗血小板特性。该药物在体外对血小板聚集、β-血小板球蛋白（βTG）释放和血栓素B2（TxB2）生成显示出显著抑制作用。然而，此类作用仅在高浓度药物（10⁻³和10⁻⁴mol/L）存在时可见，在较低浓度时则完全消失。在一小群志愿者中口服300mg该药物后，在体内未观察到作用。可以得出结论，在没有充分谨慎考虑以表明其潜在临床用途的情况下，不能推测该药物的体外特性。
